Latest Can-Fite BioPharma News & Updates

See the latest news and media coverage for Can-Fite. We track all announcements, press releases, and industry mentions in real time, all in one place.

Can-Fite BioPharma (Can-Fite)

Biopharmaceutical company developing oral drugs for oncology and inflammatory diseases

canfite.com

Last updated Today

Latest news about Can-Fite BioPharma (Can-Fite)

In short: Can-Fite achieved key clinical milestones for its drug pipeline, notably in psoriasis and pancreatic cancer, while securing new funding.

Company announcements

July 6 Can-Fite

Can-Fite completes patient enrolment for Phase 3 psoriasis interim analysis

The interim analysis follows an FDA- and EMA-agreed protocol, with results expected in Q4 2026 or Q1 2027.

July 1 Can-Fite

Can-Fite's Namodenoson meets safety endpoint in pancreatic cancer study

Median overall survival exceeded 5 months in third-line patients; one second-line patient alive over 18 months.

June 22 Can-Fite

Can-Fite publishes peer-reviewed scientific article on Piclidenoson and Namodenoson

The article demonstrates broad therapeutic potential of A3AR agonists across multiple diseases, supported by independent research.

June 2 Can-Fite

Can-Fite highlights Namodenoson's RAS inhibition in pancreatic cancer

The Phase 2a study showed prolonged disease control in patients, including one patient on therapy for 16 months.

Media coverage

July 6 Yahoo Finance

Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027

Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American...

July 1 Yahoo Finance

Why Is CANF Stock Surging Today?

Can-Fite said Namodenoson met the Phase IIa study's main safety goal and demonstrated durable overall survival.

July 1 The Globe and Mail

Can-Fite's Namodenoson Hits Safety Goal and Shows Durable Survival in Phase 2a Pancreatic Cancer Trial

Detailed price information for Can-Fite Biopharma Ltd ADR (CANF-A) from The Globe and Mail including charting and trades.

June 26 Yahoo Finance

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan...

Never miss news about Can-Fite

Track Can-Fite and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.